Positive Results Announced from Second Phase III Study of Alemtuzumab in MS/About-the-Society/News/Positive-Results-Announced-from-Second-Phase-III-S … read morePosted At: National MS Society
Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trial
Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trialMultiple Sclerosis Journal, Ahead of Print. … read morePosted At: MS Journal
The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis riskMultiple Sclerosis Journal, Ahead of Print. … read morePosted At: MS Journal
Open Enrollment Ends Feb. 15/About-the-Society/News/ACA-Open-Enrollment … read morePosted At: National MS Society
Share Why You Connect to the MS Movement During MS Awareness Week March 2-8, 2015/About-the-Society/News/Share-Why-You-Connect-to-the-MS-Movement-During-MS … read morePosted At: National MS Society
- Next story Fast Forward, LLC and EMD Serono, Inc. Announce Recipients of Funding for Multiple Sclerosis Researc
- Previous story 2012: Sweeping Advances Made in MS Research
Join Our Mailing List
- Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis
- What are the early signs of MS?
- Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis
- Treatment decisions in MS: Shifting the goal posts or changing how we see them?
- How to give an intramuscular injection
- Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry
- e-Health and multiple sclerosis: An update
- Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System
- Glutamate-sensitive imaging and evaluation of cognitive impairment in multiple sclerosis
- MS: Is a ‘rogue’ brain and lymph node interaction to blame?